Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The expertise in the characterization of transcriptomics profile in lesional psoriatic skin
and on the availability of innovative therapy for these patients.The investigators propose to
follow the modification of the skin transcriptomics profile in psoriatic patients during
successful Adalimumab biotherapy. Skin transcriptomics profiles of normal skin, psoriatic non
lesional skin, and psoriatic lesional skin before and after biotherapy will be compared. The
investigators will focus on the modification of the cytokine "signature" in these skin
lesions and of some markers of keratinocyte inflammation. The modification of the
transcriptomics profile induced by the biotherapy will be correlated to the clinical response
Psoriasis Area and Severity Index.